MeiraGTx has five programs in clinical development and a pipeline of preclinical and research programs. As part of a worldwide collaboration and license agreement, the partnership will develop,
The company plans to initiate its Phase 1/2 US multicenter clinical trial in the first half of 2019. The Phase 1 dose escalation portion of the trial will
The breakthrough therapy designation has been granted for V114 to prevent invasive pneumococcal disease (IPD) caused by the vaccine serotypes in pediatric patients aged between six weeks and
The tanezumab 5 mg treatment arm met all three co-primary endpoints at 24 weeks, demonstrating a statistically significant improvement in pain, physical function and the patients’ overall assessment
The first analysis of the tetravalent immunization against dengue efficacy study (TIDES) trial demonstrated that TAK-003 effectively prevented dengue fever caused by any of the four serotypes of
In the initial 26 week treatment period, 53.6 percent of patients (95% CI [39.6%, 67.5%]) demonstrated complete thrombotic microangiopathy (TMA) response. ULTOMIRIS provided immediate and complete inhibition of
Imbruvica in combination with obinutuzumab is said to be the first approved non-chemotherapy combination regimen for treatment-naïve patients with CLL/SLL, which is the most common form of leukemia
The acquisition is expected to be completed in the summer of 2019. The companies are entering into a strategic partnership that will see NextPharma take over production of
The deal also provides Sobi with the right to participate in payments from the US profits or losses for new medicine MEDI8897 in development for RSV-induced LRTI As
NV-5138 is a first-in-class, orally-active small molecule that directly activates mTORC1, the gatekeeper of cellular metabolism and renewal, which is suppressed in the brain of people suffering from
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.